For Manuscripts Sample Clauses

For Manuscripts. This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views of policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government." For Abstracts: (due to space limitations): "Funded by NCI Contract No. HHSN261200800001E."
Sample 1
AutoNDA by SimpleDocs
For Manuscripts. Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health under award numbers U01DK065211 (Indiana University), U01DK065184 (University of Michigan), U01DK065201 (University of North Carolina-Chapel Hill), U01DK083020 (University of Southern California), U01DK083027 (Xxxxxx Xxxxxxxxx University/Xxxxxx Xxxxxxxx Medical Center), and U24DK065176 (Duke University). Additional support is provided by the intramural programs of the NIDDK and National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Study supported by NIDDK U01/U24 grants. See DILIN website xxxxx://xxxxx.xxx/publications for a complete listing of funding sources, sites, investigators, co-investigators, coordinators, and staff. Indiana University-Purdue: Xxxx Xxxxxxxxx, PI; Xxxxxx Xxxxxxx, Sub-I; Xxx Xxxxxxxxxxx, Sub-I [Xxxxxxxx Xxxxxx, Study Coord] University of Michigan-Xxx Arbor: Xxx Xxxxxxx, PI; Xxxxx Xxxxxxxxx, Sub-I; Xxxxxxx Xxxx, Sub-I; Xxxxxxxx Xxxxxxx, Sub-I [Xxxxxx Xxxxxxxx, Study Coord] University of North Carolina-Chapel Hill: Xxxx Xxxxxxx, PI; Xxx Xxxxxxx, Sub-I [Xxxxx Xxxxx, Study Coord; BB Behera, Study Coord; Xxxxxxx Xxxxxxx, Study Coord]
Sample 1
For Manuscripts. This project has been funded in whole or in part with Federal funds from the Department of Homeland Security under BOA No. [insert # here], Task Order No. [insert # here] The content of this publication does not necessarily reflect the views or policies of the Department of Homeland Security, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government."
Sample 1

Related to For Manuscripts

  • Protocols Each party hereby agrees that the inclusion of additional protocols may be required to make this Agreement specific. All such protocols shall be negotiated, determined and agreed upon by both parties hereto.

  • Publications Neither Party shall publicly present or publish results of studies carried out under this Agreement (each such presentation or publication a “Publication”) without the opportunity for prior review by the other Party, except to the extent otherwise required by Applicable Law, in which case Section 12.3 shall apply with respect to disclosures required by the SEC and/or for regulatory filings. The submitting Party shall provide the other Party the opportunity to review any proposed Publication at least thirty (30) days prior to the earlier of its presentation or intended submission for publication. The submitting Party agrees, upon request by the other Party, not to submit or present any Publication until the other Party has had thirty (30) days to comment on any material in such Publication. The submitting Party shall consider the comments of the other Party in good faith, but will retain the sole authority to submit the manuscript for Publication; provided that the submitting Party agrees to delay such Publication as necessary to enable the Parties to file a Patent if such Publication might adversely affect such Patent. The submitting Party shall provide the other Party a copy of the Publication at the time of the submission or presentation. Notwithstanding the foregoing, BMS shall not have the right to publish or present Ambrx’s Confidential Information without Ambrx’s prior written consent, and Ambrx shall not have the right to publish or present BMS’ Confidential Information without BMS’ prior written consent. Each Party agrees to acknowledge the contributions of the other Party, and the employees of the other Party, in all publications as scientifically appropriate. This Section 12.4 shall not limit and shall be subject to Section 12.5. Nothing contained in this Section 12.4 shall prohibit the inclusion of information in a patent application claiming, and in furtherance of, the manufacture, use, sale or formulation of a Compound, provided that the non-filing Party is given a reasonable opportunity to review, comment upon and/or approve the information to be included prior to submission of such patent application, where and to the extent required by Article 9 hereof. Notwithstanding the foregoing, the Parties recognize that independent investigators have been engaged, and will be engaged in the future, to conduct Clinical Trials of Compounds and Products. The Parties recognize that such investigators operate in an academic environment and may release information regarding such studies in a manner consistent with academic standards; provided that each Party will use reasonable efforts to prevent publication prior to the filing of relevant patent applications and to ensure that no Confidential Information of either Party is disclosed.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!